Efficient Identification of High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Plasma Samples by Pooling Method.
暂无分享,去创建一个
S. Boyd | K. Nguyen | Lorna Tolentino | O. Wirz | T. Pham | Suchitra Pandey | K. Röltgen
[1] M. Franchini,et al. The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19 , 2021, Life.
[2] W. Lim,et al. Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .
[3] John D. Davis,et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 , 2020, The New England journal of medicine.
[4] R. Goel,et al. Promoting access to COVID-19 convalescent plasma in low- and middle-income countries , 2020, Transfusion and Apheresis Science.
[5] E. Pastorello,et al. Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost? , 2020, Clinical and Molecular Allergy.
[6] Matthew S. Miller,et al. Immunological considerations for COVID-19 vaccine strategies , 2020, Nature Reviews Immunology.
[7] Anil M. Tharappel,et al. Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development , 2020, Virus Research.
[8] R. Tibshirani,et al. SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness , 2020, medRxiv.
[9] R. Olsen,et al. Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality , 2020, The American Journal of Pathology.
[10] H. Bach,et al. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks , 2020, Clinical Microbiology and Infection.
[11] A. Hussain,et al. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies , 2020, Biomedicine & Pharmacotherapy.
[12] E. Hod,et al. Antibody responses to SARS-CoV2 are distinct in children with MIS-C compared to adults with COVID-19 , 2020, medRxiv.
[13] E. Wood,et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. , 2020, The Cochrane database of systematic reviews.
[14] I. Kamenidou,et al. Achieving a Covid-19 Free Country: Citizens Preventive Measures and Communication Pathways , 2020, International journal of environmental research and public health.
[15] M. Ben-Shoshan,et al. COVID-19 and comorbidities: a systematic review and meta-analysis , 2020, Postgraduate medicine.
[16] J. Pagel,et al. Use of convalescent plasma in hospitalized patients with COVID-19: case series , 2020, Blood.
[17] S. Lauer,et al. Serology-informed estimates of SARS-COV-2 infection fatality risk in Geneva, Switzerland , 2020, medRxiv.
[18] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.
[19] C. Bethel,et al. Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies , 2020, bioRxiv.
[20] Douglas R. McDonald,et al. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!☆ , 2020, Clinical Immunology.
[21] Goutam Rath,et al. A Review of Current Interventions for COVID-19 Prevention , 2020, Archives of Medical Research.
[22] Jun Yuan,et al. Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.
[23] I. Ali,et al. COVID-19: Disease, management, treatment, and social impact , 2020, Science of The Total Environment.
[24] Kaijun Jiang,et al. SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup , 2020, Current protocols in microbiology.
[25] Vitória S. Foletto,et al. Drug repositioning is an alternative for the treatment of coronavirus COVID-19 , 2020, International Journal of Antimicrobial Agents.
[26] Yan Peng,et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.
[27] Bin Zhang,et al. Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection , 2020, Chest.
[28] Shangen Zheng,et al. Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2 , 2020, Journal of Clinical Microbiology.
[29] Jing Yuan,et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. , 2020, JAMA.
[30] Shibo Jiang,et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine , 2020, Cellular & Molecular Immunology.
[31] Frank Grosveld,et al. A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.
[32] Guangdi Li,et al. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.
[33] Gengfu Xiao,et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.
[34] C. Blandizzi,et al. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline , 2020, mAbs.
[35] Fang Li,et al. Structure, Function, and Evolution of Coronavirus Spike Proteins. , 2016, Annual review of virology.